Compugen and Biosite Expand Dx-Development Alliance | GenomeWeb
NEW YORK (GenomeWeb News) — Biosite will have access to more of Compugen’s diagnostic and immunoassay biomarkers under a renewed and expanded partnership and licensing agreement, Compugen said today.
 
In June 2005 the companies penned an alliance to develop and commercialize immunoassay-based diagnostics for cardiovascular and oncology indications based on several of Compugen’s gene targets.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.